Wei Jing, Zhang Weiyuan, Feng Limin, Gao Wanli
Beijing Obstetrics and Gynecology Hospital, Capital Medical University Department of Obstetrics and Gynecology, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China.
Medicine (Baltimore). 2017 Sep;96(37):e8034. doi: 10.1097/MD.0000000000008034.
There are some fertility-sparing treatments in patients with early endometrial cancer (EEC) or atypical complex hyperplasia (ACH), and the objective is to compare them by evaluating the oncologic and reproductive outcomes.
We searched the published literature using Medline, Cochrane, EMBASE, and Google Scholar databases up to January 3, 2017, with various combinations of keywords fertility-sparing treatments, progesterone, progestin, intrauterine devices, early endometrial cancer, and atypical complex hyperplasia. The primary endpoint is the complete response (CR) rate, and the secondary endpoints are the partial response (PR) rate, relapse rate (RR), pregnancy rate, and live birth rate.
Twenty-eight studies containing 1038 women with EEC or ACH were included for review and meta-analysis. The results demonstrated that women with EEC or ACH managed with progestin had a pooled CR rate of 71% (95% confidence interval [CI]: 63-77%). The pooled pregnancy outcomes showed that 34% of women taking progestin treatment for EEC or ACH became pregnant (95% CI: 30-38%); however, only 20% of them delivered live newborns. The pooled CR rate for women using intrauterine device (IUD) was 76% (95% CI: 67-83%), and pooled RR was 9% (95% CI: 5-17%). The pregnancy rate for women whom underwent IUD was 18% (95% CI: 7-37%), and 14% of them delivered live newborns. In patients using progestin plus IUD, the pooled CR rate was 87% (95% CI: 75-93%); among those patients, 40% became pregnant (95% CI: 20-63%), and 35% delivered live newborns. There is no publication bias for the CR rate.
For patients with EEC and ACH, treatments with progestin, with or without IUD, or IUD alone can reach good CR rate; however, the pregnancy outcomes might be worse in patients treated with IUD alone. Further randomized-controlled studies are warranted to find out a better solution.
早期子宫内膜癌(EEC)或非典型复杂性增生(ACH)患者有一些保留生育功能的治疗方法,目的是通过评估肿瘤学和生殖结局来比较这些方法。
我们使用Medline、Cochrane、EMBASE和谷歌学术数据库检索截至2017年1月3日发表的文献,使用保留生育功能治疗、孕酮、孕激素、宫内节育器、早期子宫内膜癌和非典型复杂性增生等关键词的各种组合。主要终点是完全缓解(CR)率,次要终点是部分缓解(PR)率、复发率(RR)、妊娠率和活产率。
纳入28项研究,共1038例EEC或ACH女性进行综述和荟萃分析。结果表明,接受孕激素治疗的EEC或ACH女性的合并CR率为71%(95%置信区间[CI]:63-77%)。汇总的妊娠结局显示,34%接受孕激素治疗的EEC或ACH女性怀孕(95%CI:30-38%);然而,其中只有20%分娩活产新生儿。使用宫内节育器(IUD)的女性的合并CR率为76%(95%CI:67-83%),合并RR为9%(95%CI:5-17%)。接受IUD治疗的女性的妊娠率为18%(95%CI:7-37%),其中14%分娩活产新生儿。在使用孕激素加IUD的患者中,合并CR率为87%(95%CI:75-93%);在这些患者中,40%怀孕(95%CI:20-63%),35%分娩活产新生儿。CR率无发表偏倚。
对于EEC和ACH患者,单独使用孕激素治疗、使用或不使用IUD,或单独使用IUD均可达到良好的CR率;然而,单独使用IUD治疗的患者妊娠结局可能较差。需要进一步的随机对照研究以找到更好的解决方案。